Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(6):401-405
DOI: 10.5428/pcar20180601
Advances in biotherapy of diabetic nephropathy
1. SHEN YiLan(Department of Nephrology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China medulla12@163.com)
2. DING Tao(Department of Nephrology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China )
3. MEI XiaoBin(Department of Nephrology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China meixiaobin168@163.com)
ABSTRACT  Diabetic nephropathy(DN),one of the causes of end-stage renal disease,is closely related to increased incidence of cardiovascular morbidity and mortality.Current treatment approaches of DN include strict control of blood glucose,lowering blood pressure and reducing albuminuria by renal-angiotensin-aldosterone system blockers.However,these are only symptomatic treatment,and effective treatment of DN is still not available.This review explores the role and clinical research advances of some biomolecules in the pathogenesis of DN,such as glucagon-like peptide-1(GLP-1),integrin αVβ3,endothelin A(ETA),chemokine receptor 2(CCR2),etc.
Welcome to PCAR! You are the number 52 reader of this article!
Please cite this article as:
SHEN YiLan,DING Tao,MEI XiaoBin,. Advances in biotherapy of diabetic nephropathy[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(6): 401-405.
References:
1. Bjornstad P,Cherney D,Maahs D M.Early diabetic nephropathy in type 1 diabetes: new insights[J].Curr Opin Endocrinol Diabetes Obes,2014,21(4):279-286.
2. Villar E,Remontet L,Labeeuw M,et al.Effect of age,gender,and diabetes on excess death in end-stage renal failure[J].J Am Soc Nephrol,2007,18(7):2125-2134.
3. Schrijvers B F,De Vriese A S,Flyvbjerg A.From hyperglycemia to diabetic kidney disease:the role of metabolic,hemodynamic,intracellular factors and growth factors/cytokines[J].Endocr Rev,2004,25(6):971-1010.
4. Yu S M,Bonventre J V.Acute kidney injury and progression of diabetic kindey disease[J].Adv Chronic Kidney Dis,2018,25(2):166-180.
5. CHEN JianChun,CHEN JianKang,Harris R C.EGF receptor deletion in podocytes attenuates diabetic nephropathy[J].J Am Soc Nephrol,2015,26(5):1115-1125.
6. Sutariya B,Jhonsa D,Saraf M N.TGF-β:the connecting link between nephropathy and fibrosis[J].Immunopharmacol Immunotoxicol,2016,38(1):39-49.
7. Wilson P G,Thompson J C,Yoder M H,et al.Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition[J].J Lipid Res,2017,58(12):2264-2274.
8. Voelker J,Berg P H,Sheetz M,et al.Anti-TGF-β1 antibody therapy in patients with diabetic nephropathy[J].J Am Soc Nephrol,2017,28(3):953-962.
9. Pozzi A,Zent R.Integrins in kidney disease[J].J Am Soc Nephrol,2013,24(7):1034-1039.
10. Yoon S,Gingras D,Bendayan M.Alterations of vitronectin and its receptor αv integrin in the rat renal glomerular wall during diabetes[J].Am J Kidney Dis,2001,38(6):1298-1306.
11. Maile L A,Busby W H,Gollahon K A,et al.Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs[J].Endocrinology,2014,155(12):4665-4675.
12. ZHOU XiaoYan,ZHANG Ji,Haimbach R,et al.An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model[J].Pharmacol Res Perspect,2017,5(5):1-14.
13. Tanaka T,Higashijima Y,Wada T,et al.The potential for renoprotection with incretin-based drugs[J].Kidney Int,2014,86(4):701-711.
14. Fujita H,Morii T,Fujishima H,et al.The protective roles of GLP-1R signaling in diabetic nephropathy:possible mechanism and therapeutic potential[J].Kidney Int,2014,85(3):579-589.
15. Mann J F E,rsted D D,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes[J].N Engl J Med,2017,377(9):839-848.
16. de Zeeuw D,Coll B,Andress D,et al.The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy[J].J Am Soc Nephrol,2014,25(5):1083-1093.
17. Scholten D J,Canals M,Maussang D,et al.Pharmacological modulation of chemokine receptor function[J].Br J Pharmacol,2012,165(6):1617-1643.
18. YOU HanNing,GAO Ting,Raup-Konsavage W M,et al.Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice[J].Kidney Int,2017,91(3):671-682.
19. de Zeeuw D,Bekker P,Henkel E,et al.The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial[J].Lancet Diabetes Endocrinol,2015,3(9):687-696.
20. Kanasaki K,Shi S,Kanasaki M,et al.Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen[J].Diabetes,2014,63(6):2120-2131.
21. Tani S,Nagao K,Hirayama A.Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor,vildagliptin: a pilot study[J].Am J Cardiovasc Drugs,2013,13(6):443-450.
22. Groop P H,Cooper M E,Perkovic V,et al.Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction[J].Diabetes Care,2013,36(11):3460-3468.
23. Fang L,Radovits T,Szabó G,et al.Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3′,5′ guanosine monophosphate (cGMP) level in podocytes[J].Nephrol Dial Transplant,2013,28(7):1751-1761.
24. Jeong K H,Lee T W,Ihm C G,et al.Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats[J].Am J Nephrol,2009,29(3):274-282.
25. Scheele W,Diamond S,Gale J,et al.phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy[J].J Am Soc Nephrol,2016,27(11):3459-3468.
26. Gill P S,Wilcox C S.NADPH oxidases in the kidney[J].Antioxid Redox Signal,2006,8(9-10):1597-1607.
27. Gorin Y,Cavaglieri R C,Khazim K,et al.Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes[J].Am J Physiol Renal Physiol,2015,308(11):F1276-F1287.
28. Cha J J,Min H S,Kim K T,et al.APX-115,a first-in-class pan-NADPH oxidase (Nox) inhibitor,protects db/db mice from renal injury[J].Lab Invest,2017,97(4):419-431.
29. O’Sullivan L A,Liongue C,Lewis R S,et al.Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease[J].Mol Immunol,2007,44(10):2497-2506.
30. ZHANG HongYu,Nair V,Saha J,et al.Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice[J].Kidney Int,2017,92(4):909-921.
31. Berthier C C,ZHANG HongYu,Schin M,et al.Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy[J].Diabetes,2009,58(2):469-477.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口